An immunity-driven modelling framework for epidemics of non-sterilising infections

Daniel Stocks (Daniel.Stocks@bristol.ac.uk)[1], Amy C Thomas
(AmyC.Thomas@bristol.ac.uk)[2], Ellen Brooks-Pollock
(Ellen.Brooks-Pollock@bristol.ac.uk)[2,3], and Leon Danon
(L.Danon@bristol.ac.uk)[1,3,4]

[1]Department of Engineering Mathematics, University of Bristol
[2]Population Health Sciences, Bristol Medical School, University of
Bristol
[3]Jean Golding Institute, University of Bristol
[4]Equal contribution

Abstract

Protecting populations against infections with non-sterilising immunity, such as COVID-19 and influenza, presents a major public health challenge. Population models used to guide public health and vaccination strategies are often incompatible with individual-level immunological and virological data. To address this gap, we develop a novel and flexible mathematical framework that links within-host immune and viral dynamics to between-host transmission, bridging multiple scales from individuals to populations.

Our approach derives infectiousness from viral load and protection against reinfection from time-varying levels of immune factors, allowing population-level epidemiological trajectories to emerge as the summation of individual infectiousness and immunity. As an example, we use a phenomenological model of viral load quantified in a SARS-CoV-2 human challenge study, and a mechanistic model of binding antibody levels, fit to cross-sectional SARS-CoV-2-specific binding antibody levels post-vaccination.

We demonstrate the ability of this framework to go beyond conventional compartmental models by predicting times to reinfection and the number of infections experienced by individuals. As a result, we show that immune responses fundamentally shape epidemic dynamics. Low correlations between antibody levels and protection lead to frequent reinfections and endemic circulation, whereas high correlations produce recurrent and explosive outbreaks.

To demonstrate the potential of this modelling approach to estimate the protective power and reinfection dynamics across diverse immune his-

tories, we recover the model parameters by fitting to simulated case data. This interdisciplinary approach provides new insights into the drivers of irregular epidemic patterns and can inform vaccination strategies for pathogens with non-sterilising immunity.

1   Introduction

Vaccination and infection can prevent infection, reinfection, and the development of clinical disease by inducing an immune response. Immune responses constitute a complex web of often simultaneous interactions between stimuli, immune cells, and effector proteins that proliferate or are produced and then wane, potentially at different times and rates post-exposure (1). These individual-level within-host processes and resulting protective mechanisms play a key role in driving population-level epidemiological dynamics (2). Understanding how immunity to a disease changes over time is vital for accurately predicting future epidemic trajectories and optimising vaccine strategies (3; 4).

For diseases such as COVID-19, mumps, and malaria, for which immunity is non-sterilising and wanes over time (5; 6; 7), reinfection and repeat outbreaks (8; 9) are commonly observed. The relationship between immune dynamics and protection is needed for defining risk groups and informing vaccine strategy. It can improve predictions of future protection, quantifying the benefits of different vaccine regimes and immune histories by helping quantify potential reductions in case and hospitalisation rates. The wealth of serological and virological data collected during the COVID-19 pandemic offers a unique opportunity to develop methodologies that estimate these profiles of protection and bridge within-host and population-level dynamics.

Previous research has established that both binding and neutralizing antibody levels correlate with reduced viral load (10; 11) and reduced likelihood of reinfection (12; 13; 14), as well as estimated how protection varies with antibody level (13; 15). However, these estimations do not account for how varying infectious pressure may distort estimates of protection. To disentangle the effects of infectious pressure and individual protection, individual immunity can be incorporated as part of a population-level mathematical model of disease dynamics, and estimates of the protection associated with antibody level can be validated by comparing predicted and observed times until reinfection.

However, conventional mathematical models that capture the complexity of within-host dynamics often become cumbersome. Within-host dynamics are incorporated by expanding the number of compartments in the infectious and recovered classes to create discretised versions of integrodifferential equations (16; 17; 18). The expansion of these classes allows for varying infectiousness and protection (19; 3; 20; 21) or varying rates of recovery and waning immunity (18; 22; 23) to vary with time since exposure. If these varying rates are informed by within-host models, they can link within-host and epidemiological dynamics. However, the number of states required to incorporate this complexity can be very large, especially when reinfection dynamics need to be extracted.

Consequently, models usually only track a single reinfection, if any, and rarely estimate the rate of reinfection (21; 24; 25; 26). This limits their capacity to further our understanding of how immune history affects protection.

To fill this gap, we propose a modular modelling framework that tracks all reinfections and accounts for variation in immunity and infectivity based on time since infection. The framework is flexible and can be informed by any reasonable model of within-host dynamics, enabling within-host and population-level dynamics to be linked and the effect of immune histories on protection to be estimated and validated. As an example, we use a mechanistic model of binding antibody levels following COVID-19 vaccination (27) and fit a phenomenological model to longitudinal quantitative PCR (qPCR) (28). We demonstrate how within-host models can be transformed into probabilities of being susceptible and infectious at any given time post-infection. Using these time-varying infectious and protective profiles, we simulate an epidemic and extract information on the timing and frequency of reinfection. We then demonstrate how the parameters used to simulate the epidemic can be recovered when the model is fit to case data, showing that with this framework, profiles of protection can be estimated from population-level data and validated using serological observations.

2 Methods

2.1 Modelling Population Dynamics Through a Convolution of Individual Infectivity and Immunity

To mathematically model population-level epidemiological dynamics as driven by within-host dynamics, we propose a convolution that accumulates individual probabilities of being infectious and susceptible into a population-level average infectiousness and susceptibility. The probabilities of being infectious or susceptible are derived from within-host dynamics. Figure 1 shows a schematic of the model we propose, and table 1 contains a description of all parameters used. In the model, each individual has a time-varying profile of infectiousness and susceptibility to infection. The overall infectiousness and susceptibility of the population are the sum of individual infectiousness and susceptibility. In the simplest case of the model, individual infectiousness and susceptibility are memoryless so that they are solely dependent on time since last infection, and individuals are categorised by when they were last infected. Under this framework, individuals are both partially protected and partially infectious simultaneously. The proportion of people that are infected at a given time is the product of average infectiousness, average susceptibility, and a contact rate (mass-action mixing).

Defining $P_I(h)$ and $P_S(h)$ as the probability of being infectious and susceptible, h time since last infection (otherwise defined as individual infectiousness and susceptibility profiles), and $I_n(t)$ and $S(t)$ as the average probability of being infectious and susceptible at the population level at time t:

Infectivity-Immunity Convolution Model		
Parameter	Description	Units
ξ	Average contact rate	people $\cdot$ days^{-1}
$P_I(h)$	Probability of being infectious h time post-infection	$-$
$P_S(h)$	Probability of being susceptible to infection h time post-infection	$-$
Compartmental Models		
ξ	Average contact rate	days^{-1}
η	Probability of being infectious	$-$
δ	Probability of being immune	$-$
$\frac{1}{\phi}$	Average time until recovery	days
$\frac{1}{\lambda}$	Average time until constant immunity	days
Antibody Model (27)		
A_0	Initial antibody level	Ab
Φ_s	Plasmablast antibody production capacity	cells $\cdot$ Ab $\cdot$ days^{-1}
Φ_l	Plasmacell antibody production capacity	cells $\cdot$ Ab $\cdot$ days^{-1}
μ_s	Average plasamblast decay rate	days^{-1}
μ_a	Average antibody decay rate	days^{-1}
Viral Load Model		
d	Horizontal shift	$-$
α	Rate parameter	$-$
κ	Scale parameter	$-$

Table 1: The description and units of parameters and functions used in respective models. Ab is an abbreviation of antibodies.

$$S(t) = S_0\theta_t^{S_0} + I_0\theta_{0,t}^{S}P_S(t) + \xi \int_0^t S(\tau)I_n(\tau)\theta_{\tau,t}^{S}P_S(t-\tau)\, d\tau, \qquad \text{(1a)}$$

$$I_n(t) = I_0\theta_{0,t}^{S}P_I(t) + \xi \int_0^t S(\tau)I_n(\tau)\theta_{\tau,t}^{S}P_I(t-\tau)\, d\tau, \qquad \text{(1b)}$$

$$\theta_t^{S_0} = \exp\left(-\xi \int_0^t I_n(h)\, dh\right), \qquad \text{(1c)}$$

$$\theta_{\tau,t}^{S} = \exp\left(-\xi \int_0^{t-\tau} P_S(h)\, I_n(\tau+h)\, dh\right), \qquad \text{(1d)}$$

where S_0 is the proportion of the population who have not experienced an infection at $t = 0$, I_0 is proportion of the population infected at $t = 0$, ξ is the average contact rate, $\theta_t^{S_0}$ is the probability an infected individual has had a primary infection by time t, and $\theta_{\tau,t}^{S}$ is the probability an individual, last

Figure 1: **Schematic of how within-host virological and immunological dynamics are used to produce population dynamics.** The within-host dynamics are summarised as susceptibility and infectivity. These quantities are estimated from immune factor data (such as antibodies) and viral load following vaccination or infection. The population dynamics are the cumulative susceptibility and infectivity of individuals who have been exposed.

infected at time τ, has been reinfected by time t. The probability of reinfection at each time is dictated by the infectious pressure experienced, $\xi I_n(\tau + s)$, and the probability of being susceptible while experiencing that pressure; 1 if not yet infected, and $P_S(h)$ when a person's last infection occurred h time ago.

Equations (1a) and (1b) are summations over the susceptibility and infectiousness of individuals last infected at different points in time. The equations capture the average infectiousness and susceptibility of the population through a weighted sum of the proportion of the population infected at each time and how infectious/susceptible they are, given the time that has elapsed between their infection and the current point in time. As we assume that uninfected individuals are completely susceptible, the proportion of the population not infected at $t = 0$ (S_0) that remains uninfected ($\theta_t^{S_0}$) is equal to the susceptibility they contribute to the population average. The proportion of the population infected at $t = 0$ (I_0) that have not been reinfected ($\theta_{0,t}^S$) contribute $P_S(t)$ and $P_I(t)$ to the average population susceptibility of infectiousness respectively. The proportion of the population last infected at each subsequent point in time ($\xi S(\tau) I_n(\tau)$) that has not been reinfected by time t ($\theta_{\tau,t}^S$) contributes $P_S(t - \tau)$ and $P_I(t - \tau)$

to the average population susceptibility and infectiousness respectively.

Equations (1) are coupled Volterra integrals with nonlinear kernels that cannot be solved analytically or readily. However, when equations (1) are approximated by the trapezium rule, the equations for $I(t)$ and $S(t)$ become simultaneous equations and can be rearranged to depend only on previous values of I and S, and solved iteratively (see section 1 of the supplementary material for details).

2.2 Tracking Reinfection

Reinfection is the observable and meaningful consequence of failed protection. Being able to quantify it and link it to immune dynamics with mathematical models enables a better understanding of the effects of different immune histories and the ability to validate estimated profiles of protection with observed cases of reinfection.

In the convolution model we propose, reinfections are organically tracked through $\theta_{\tau,t}^S$, the survival function of reinfection. The probability of reinfection at time t for individuals last infected at time τ is given by the adjoining probability density function of $\theta_{\tau,t}^S$. The probability density functions for all times of previous infection can be combined into a matrix with rows for the time of the previous infection and columns for the time of the next infection. This is a transition matrix from one infection to the next, $\boldsymbol{\Theta}_S$.

$$\boldsymbol{\Theta}_S = \frac{d}{dt}(1 - \theta_{\tau,t}^S) = \xi P_s(t - \tau)I_n(t)\theta_{\tau,t}^S. \tag{2}$$

Since reinfection in the convolution is a Markovian process (i.e., only dependent on the previous infection), raising $\boldsymbol{\Theta}_S$ to the power of r gives the probability of being reinfected for the rth time at time t given a primary infection at time τ.

The probability of being initially infected at time t is

$$\boldsymbol{\Theta}_{S_0} = \frac{d}{dt}(1 - \theta_{\tau,t}^{S_0}) = \xi I_n(t)\theta_{\tau,t}^{S_0}. \tag{3}$$

2.3 Comparative Compartmental Model

An equivalent compartmental model to the convolution model we propose would need many infectious and recovered states with varying levels of infectiousness and immunity. We use n infectious states with different probabilities of being infectious, η_i, and m recovered states with different probabilities of being susceptible, δ_j. When infected, individuals transition through the infectious states in order and then through the recovered states in order. Individuals can be reinfected in any of the recovered states. Once reinfected, they transition back to the initial infectious state. If they are not reinfected beforehand, they will transition to the mth recovered state and remain there until they are reinfected. We denote the average time until recovery as $\frac{1}{\phi}$, and the average time to reach the final recovered state as $\frac{1}{\lambda}$. Defining $S(t)$ as the uninfected proportion of the

population, I_i as the proportion of the population in the ith infectious state, and R_j as the proportion of the population in the jth recovered state,

$$\dot{S}(t) = -\xi S(t) \sum_{i=1}^{n} \eta_i I_i(t), \tag{4a}$$

$$\dot{I}_1(t) = \xi \sum_{i=1}^{n} \eta_i I_i(t) \Big(S(t) + \sum_{j=1}^{m} \delta_j R_j(t) \Big) - n\phi I_1, \tag{4b}$$

$$\dot{I}_i(t) = n\phi(I_{i-1}(t) - I_i(t)), \tag{4c}$$

$$\dot{R}_1(t) = n\phi I_n(t) - (m-1)\lambda R_1(t) - \xi \delta_1 R_1(t) \sum_{i=1}^{n} \eta_i I_i(t), \tag{4d}$$

$$\dot{R}_j(t) = (m-1)\lambda(R_{j-1}(t) - R_j(t)) - \xi \delta_j R_j(t) \sum_{i=1}^{n} \eta_i I_i(t), \tag{4e}$$

$$\dot{R}_m(t) = (m-1)\lambda R_{m-1}(t) - \xi \delta_m R_m(t) \sum_{i=1}^{n} \eta_i I_i(t). \tag{4f}$$

2.4 Informing infectiousness and susceptibility to infection with within-host dynamics

To incorporate immune dynamics into population-level models, we must derive from within-host data mathematical representations of the magnitude and longevity of infectiousness and protection. The framework we propose can incorporate any reasonable model of within-host dynamics. We use a phenomenological model of RT-qPCR viral load data (28) to derive infectiousness and a mechanistic model of binding antibody level post-vaccination (29) to derive protection.

Viral load at time h following infection at $h = 0$ can be represented by the function

$$V(h) = (h+d)^{\alpha-1} e^{-\kappa(h+d)}, \tag{5}$$

where d is an offset in time to allow for non-zero values at $h = 0$, and α and κ are shape and rate parameters (see section 2 of the supplementary material for details). A mechanistic description of antibody levels at time h following infection at $h = 0$ is (27)

$$A(h) = \frac{\Phi_l}{\mu_a} + \frac{\Phi_s}{\mu_a - \mu_s} e^{-\mu_s h} + \left(A_0 - \frac{\Phi_l}{\mu_a} - \frac{\Phi_s}{\mu_a - \mu_s} \right) e^{-\mu_a h}, \tag{6}$$

where μ_a and μ_s are the decay rates of antibodies and short-lived plasma cells, respectively, Φ_s and Φ_l are the productive capacities of short-lived and long-lived plasma cells, respectively, and A_0 is the initial level of antibody.

Viral load and antibody level can be translated into the odds of being infectious and protected to link within-host and population-level dynamics. For

this, we use a logistic function,

$$G(x; K) = \frac{x}{x + K},\qquad(7)$$

where K is a scaling parameter. Hence, we define infectious and susceptibility

Figure 2: **The time-varying within-host dynamics of the convolution and compartmental models.** A) The infectious and susceptibility profiles post-infection. The solid line is the best fit, and the shaded regions are the 95% CrI of the profiles. $K_V = 3 \times 10^6$ and $K_A = 2 \times 10^3$, the parameters of the antibody model are taken from (27) and the parameters of the viral load model are given in section 2 of the supplementary material. B) The probability of being infectious, η, and susceptible, δ, post-infection/recovery when different numbers of infectious and recovered compartments are used, (n, m). The dotted lines are the best fit $P_I(h)$ and $P_S(h)$, as presented in A), in the graph of compartmental infectiousness and compartmental susceptibility, respectively.

profiles as

$$P_I(h) = G(V(h); K_V), \tag{8}$$

$$P_S(h) = \begin{cases} 0 & h \leq \frac{1}{\phi}, \\ 1 - G(A(h); K_A) & h > \frac{1}{\phi}. \end{cases} \tag{9}$$

$P_S(h)$ is 0 for $h \leq \frac{1}{\lambda}$ so that it aligns with the assumptions of compartmental models (for comparative purposes) and to account for faster-acting immune processes (such as the innate immune system) that will contribute to an individual's immunity early on in infection.

Figure 2 shows $P_I(h)$ and $P_S(h)$ when $K_V = 3 \times 10^6$ and $K_A = 2 \times 10^3$. Figure 2 also shows how increasing the number of compartments in equations (4) allows the varying probabilities of being infectious, η_i, and susceptible, δ_j, to tend towards the continuous profiles, $P_I(h)$ and $P_S(h)$. Details of η_i and δ_j calculations can be found in section 5 of the supplementary material.

2.5 Informing within-host models

The parameters used in equation (5) are fit to RT-qPCR data collected via throat swabs from $18 - 29$ year olds (28) (see section 2 of the supplementary material for details) and the parameters used in equation (6) are taken from (27), where the model is fit to binding antibody data from $16 - 34$ year-olds vaccinated with two doses of BNT162b2 (29).

2.6 Recovering K_V and K_A from simulated data

To show that individual profiles of infectiousness and immunity can potentially be estimated from population-level data, we simulate case data from the early stage of an outbreak and fit the convolution model to it. We assume the only unknowns are K_V, K_A, and initial incidence. Full details of the simulation and fitting procedures can be found in section 6 of the supplementary material.

3 Results

3.1 The convolution model better incorporates changing immunity into model dynamics

The average population infectiousness and susceptibility produced under both modelling frameworks are shown in Figure 3. When there is only one infectious and one recovered compartment in the compartmental model, it predicts a single wave followed by a constant, endemic disease. As the number of compartments increases, so does the height of the peaks. However, even when there are 20 infectious compartments and 100 recovered compartments, the model still predicts a smaller epidemic than the convolution model. This suggests that compartmental models have the potential to underestimate the magnitude and frequency of waves when infectivity and immunity vary post-infection.

Figure 3: **Population average infectiousness and susceptibility.** A) Population average infectiousness and B) population average susceptibility as found by the convolution model and the compartmental model with 1 to 20 infectious, and 1 to 100 recovered compartments. The population average infectiousness in the compartmental models is $\sum_{i=1}^{n} \eta_i I_i(t)$. The average population susceptibility in the compartmental model is $S(t) + \sum_{j=1}^{m} \delta_j R_j(t)$. Dashed and solid lines are the population dynamics of compartmental and convolution models, respectively.

3.2 Determining the number and timings of reinfections in the convolution model

The timings and number of reinfections can be extracted from the convolution model. The transition matrices for 2nd, 3rd, and 4th infections ($\boldsymbol{\Theta}_S$, $\boldsymbol{\Theta}_S^2$, $\boldsymbol{\Theta}_S^3$, respectively) with each row weighted by the incidence at that time, as well as the proportion of daily incidence resulting from each reinfection are shown in Figure 4. Initially, in this scenario, reinfection either occurs very quickly (within the same wave) or approximately 150 days later in the next wave. As time progresses and the disease becomes endemic, the distribution of intervals between infections will widen and lose its multimodality, and a broader set of immune histories will occur simultaneously.

Figure 4: **The timing and number of infections predicted by the convolution model.** A) transition matrices for the 2nd, 3rd, and 4th infections, showing the probability of last being infected at a time of the vertical axis and then reinfected at a time of the horizontal axis. Darker areas indicate a higher probability and lighter areas a lower probability. B) daily incidence through time, decomposed into which infection an individual is experiencing. Here $K_V = 3 \times 10^6$ and $K_A = 2 \times 10^3$

3.3   Individual immunity drives epidemiological dynamics

The level of protection conveyed by the immune response is controlled by K_A. Varying K_A rescales the odds of higher antibody levels being associated with greater protection. Figure 5 shows the incidence and reinfection dynamics under assumptions of weak protection (high K_A) and strong protection (low K_A).

When weak protection is conveyed, an endemic state is quickly reached, and reinfection is frequent and rapid. When strong protection is conveyed, defined waves emerge. Initially, waves are dominated by the reinfection of those infected in the previous wave, but as the epidemic progresses, the waves become heterogeneous. Comparing the dynamics in Figures 4 and 5, we can see how decreasing K_A results in more distant waves with less variation in the number of reinfections individuals have experienced.

Figure 5: **Variation in population epidemiology given varying levels of protective immunity.** A) & C) are transition matrices for the 2nd, 3rd, and 4th infections, showing the probability of last being infected at a time of the vertical axis and then reinfected at a time of the horizontal axis. Darker areas indicate a higher probability and lighter areas a lower probability. B) & D) are daily incidence through time, decomposed into which infection an individual is experiencing. In A) & B) $K_V = 3 \times 10^6$ and $K_A = 4 \times 10^3$. High K_A results in weak protection. In C) & D) $K_V = 3 \times 10^6$ and $K_A = 0.5 \times 10^3$. Low K_A results in strong protection.

3.4 Assessing identifiability through recovering simulation parameters

To estimate profiles of infectivity and susceptibility from population-level data with the infectivity-immunity convolution model, it must be possible to recover the true values of K_V and K_A when fitting to population-level data.

Figure 6 shows the posterior distributions of K_V, K_A, and I_0 for four prior assumptions of K_V and K_A, and the resulting fits to the simulated positivity data. We see that the 95% CrI bound the generating process, suggesting the true values of K_V and K_A are recoverable and the model is identifiable. Further, the alignment of posterior distributions for all four priors suggests estimates are robust and support identifiability.

4 Discussion

We developed a flexible, modular mathematical framework that models population-level epidemiological dynamics as being driven by within-host virological and immunological dynamics. Our framework leverages the quantitative immunological and virological data (30), rather than reducing information to binary decisions on infection and sero-positivity. This results in more accurate predictions of epidemic dynamics than compartmental models, when immunity and infectivity are correlated with within-host dynamics. We observe near convergence between our convolution model and the compartmental model only when a large number of infectious and immune compartments are considered. Further, this framework infers infection dynamics that are otherwise lost in conventional compartmental models. The frequency, duration, number, and timing of infections throughout an epidemic are explicitly inferred, making the relationship between immune response and protective effectiveness explicit. Together, these results demonstrate the ability of the convolution model to link within-host and population-level dynamics.

When applying the convolution model to real-world outbreaks, it will be necessary to account for how demographic variables and immune history affect immune responses (31; 32; 33). It is easy to include population heterogeneity (age, sex, immunocompromised, etc.) and differing immune histories (infection, vaccination, hybrid immunity, etc.) in the convolution model if they are considered discrete categories and within-host dynamics are reset upon exposure (*e.g.* antibody levels after the second exposure can be greater than after the first, but the antibody level at infection cannot be the initial antibody level of the subsequent response). However, the framework cannot easily represent continuous interactions between immune status at infection and subsequent immune trajectories. Such modelling would require all possible immune histories (timing, number, and type of exposure) to be accounted for, which would quickly become intractable. It is possible to model these continuous interactions using partial differential equations (34). However, the current form of these frameworks cannot provide information about the dynamics of reinfection, decreasing

Figure 6: **Posterior estimates of cases, initial incidence (I_0), and scaling parameters K_V and K_A for viral load and binding antibody, and resulting infectious and susceptibility profiles under varying prior assumptions.** A) The model dynamics fitted to simulated case data with mode and 95% CrI. B) The estimated posterior distributions of initial incidence, I_0, and the scaling parameters for viral load and binding antibody, K_V and K_A, respectively. The vertical black lines are the true value of the parameters. C) The predicted infectious and susceptibility profiles.

their power to uncover insights about protection. Further, they rely on complex and difficult-to-inform within-host models (3; 35). Thus, while differential equation frameworks may capture continuous immune interactions, the convolution model offers a more tractable and interpretable approach for studying reinfection and protection at the population level.

Even when available immunological data are limited, the convolution model

can still be informed. The protective profiles of the convolution model only require the trajectories of an immune factor to be informed. Antibody dynamics can be estimated using passively collected, cross-sectional antibody responses post-vaccination (27; 29). However, these data can only inform post-vaccination dynamics. For demonstration purposes, we use them as a proxy for antibody dynamics post-infection. Future work should draw on richer data from longitudinal surveys that describe immune responses of a variety of population groups and immune histories (36). The inclusion of more diverse immune histories would allow for greater scrutiny of the variables affecting protection. Through fitting the convolution model to publicly available data (37; 38) or estimates of reinfection dynamics from longitudinal studies (36; 39), these within-host dynamics could be associated with protection against infection, hospitalisation, and death.

5   Conclusion

Here, we present the foundation of a novel and flexible modelling framework that can be extended to incorporate multiple data sources, such as vaccine uptake (38) and social contact rates (40). Whilst we drew on antibody responses following vaccination, considering immunity following different combinations of vaccination and infection will enable deeper insights into the role of hybrid immunity in the dynamics of infection and protection in epidemics of non-sterilising diseases (41; 42).

Data availability

The United Kingdom Health and Security Agency (UKHSA) dataset can be accessed by researchers; approval is on a project-by-project basis (`https://orchid.phc.ox.ac.uk/index.php/orchid-data/`).

Individual participant viral load data are published in (28).

Funding Statement

DS is supported by the Engineering and Physical Sciences Research Council (EPSRC) PhD studentship (grant number EP/W524414/1). We would like to acknowledge the help and support of the JUNIPER partnership (MRC grant no MR/X018598/1) which EBP, LD, and DS are affiliated. EBP receives funding from the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol. LD is funded by the UK Research and Innovation AI programme of the Engineering and Physical Sciences Research Council, AI for Collective Intelligence Research Hub (EPSRC grant EP/Y028392/1). AT is funded by a Wellcome Trust Early Career Award [227041/Z/23/Z].

References

[1] Murphy K, Weaver C. Janeway's Immunobiology. W.W. Norton & Company; 2016.

[2] Le A, King AA, Magpantay FMG, Mesbahi A, Rohani P. The impact of infection-derived immunity on disease dynamics. Journal of Mathematical Biology. 2021 Nov;83(6–7).

[3] Heffernan JM, Keeling MJ. Implications of vaccination and waning immunity. Proceedings of the Royal Society B: Biological Sciences. 2009 Mar;276(1664):2071-80.

[4] Barnard RC, Davies NG, Munday JD, Lowe R, Knight GM, Leclerc QJ, et al. Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. Nature Communications. 2022 Aug;13(1).

[5] Hadley E, Yoo YJ, Patel S, Zhou A, Laraway B, Wong R, et al. Insights from an N3C RECOVER EHR-based cohort study characterizing SARS-CoV-2 reinfections and Long COVID. Communications Medicine. 2024 Jul;4(1).

[6] Yoshida N, Fujino M, Miyata A, Nagai T, Kamada M, Sakiyama H, et al. Mumps virus reinfection is not a rare event confirmed by reverse transcription loop-mediated isothermal amplification. Journal of Medical Virology. 2008 Jan;80(3):517-23.

[7] Markwalter CF, Petersen JEV, Zeno EE, Sumner KM, Freedman E, Mangeni JN, et al. Symptomatic malaria enhances protection from reinfection with homologous Plasmodium falciparum parasites. PLOS Pathogens. 2023 Jun;19(6):e1011442.

[8] Choi KM. Reemergence of mumps. Korean Journal of Pediatrics. 2010;53(5):623.

[9] Lawpoolsri S, Sattabongkot J, Sirichaisinthop J, Cui L, Kiattibutr K, Rachaphaew N, et al. Epidemiological profiles of recurrent malaria episodes in an endemic area along the Thailand-Myanmar border: a prospective cohort study. Malaria Journal. 2019 Apr;18(1).

[10] He X, Chandrashekar A, Zahn R, Wegmann F, Yu J, Mercado NB, et al. Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell. 2021 Jun;184(13):3467-73.e11.

[11] Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 Aug;369(6505):806-11.

[12] Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021 Jul;39(32):4423-8.

[13] Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. 2021 May;27(7):1205-11.

[14] Goldblatt D, Alter G, Crotty S, Plotkin SA. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunological Reviews. 2022 Jun;310(1):6-26.

[15] Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nature Medicine. 2022 Feb;28(5):1072-82.

[16] Wearing HJ, Rohani P, Keeling MJ. Correction: Appropriate Models for the Management of Infectious Diseases. PLoS Medicine. 2005 Aug;2(8):e320.

[17] Lloyd AL. Destabilization of epidemic models with the inclusion of realistic distributions of infectious periods. Proceedings of the Royal Society of London Series B: Biological Sciences. 2001 May;268(1470):985-93.

[18] Blythe SP, Anderson RM. Distributed Incubation and Infectious Periods in Models of the Transmission Dynamics of the Human Immunodeficiency Virus (HIV). Mathematical Medicine and Biology. 1988;5(1):1-19.

[19] Gilchrist MA, Sasaki A. Modeling Host–Parasite Coevolution: A Nested Approach Based on Mechanistic Models. Journal of Theoretical Biology. 2002 Oct;218(3):289-308.

[20] White LJ, Medley GF. Microparasite population dynamics and continuous immunity. Proceedings of the Royal Society of London Series B: Biological Sciences. 1998 Oct;265(1409):1977-83.

[21] Krauer F, Guenther F, Treskova-Schwarzbach M, Schoenfeld V, Koltai M, Jit M, et al. Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study. BMC Medicine. 2024 Oct;22(1).

[22] Ghosh S, Volpert V, Banerjee M. An Epidemic Model with Time-Distributed Recovery and Death Rates. Bulletin of Mathematical Biology. 2022 Jun;84(8).

[23] Bhattacharya S, Adler FR. A Time Since Recovery Model with Varying Rates of Loss of Immunity. Bulletin of Mathematical Biology. 2012 Oct;74(12):2810-9.

[24] McMahon A, Robb NC. Reinfection with SARS-CoV-2: Discrete SIR (Susceptible, Infected, Recovered) Modeling Using Empirical Infection Data. JMIR Public Health and Surveillance. 2020 Nov;6(4):e21168.

[25] Viguerie A, Carletti M, Silvestri G, Veneziani A. Mathematical Modeling of Periodic Outbreaks with Waning Immunity: A Possible Long-Term Description of COVID-19. Mathematics. 2023 Dec;11(24):4918.

[26] Rodriguez-Maroto G, Atienza-Diez I, Ares S, Manrubia S. Vaccination strategies in structured populations under partial immunity and re-infection. Journal of Physics A: Mathematical and Theoretical. 2023 Apr;56(20):204003.

[27] Stocks D, Thomas A, Finn A, Danon L, Brooks-Pollock E. Mechanistic models of humoral kinetics following COVID-19 vaccination. Journal of The Royal Society Interface. 2025 Jan;22(222).

[28] Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, et al. Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults. Nature Medicine. 2022 Mar;28(5):1031-41.

[29] Whitaker H, Tsang RSM, Button E, Andrews N, Byford R, Borrow R, et al. Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network. Journal of Infection. 2022 Jun;84(6):814-24.

[30] Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, et al. Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science. 2021 Jul;373(6552).

[31] Hornsby H, Nicols AR, Longet S, Liu C, Tomic A, Angyal A, et al. Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history. Nature Communications. 2023 Aug;14(1).

[32] Neale I, Ali M, Kronsteiner B, Longet S, Abraham P, Deeks AS, et al. CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study. mBio. 2023 Oct;14(5).

[33] Hodgson D, Liu Y, Carolan L, Mahanty S, Subbarao K, Sullivan SG, et al. Memory B cell proliferation drives differences in neutralising responses between ChAdOx1 and BNT162b2 SARS-CoV-2 vaccines. Frontiers in Immunology. 2025 Mar;16.

[34] Barbarossa MV, Polner M, Röst G. Temporal Evolution of Immunity Distributions in a Population with Waning and Boosting. Complexity. 2018 Jan;2018(1).

[35] Heffernan JM, Keeling MJ. An in-host model of acute infection: Measles as a case study. Theoretical Population Biology. 2008 Feb;73(1):134-47.

[36] Atti A, Insalata F, Carr EJ, Otter AD, Castillo-Olivares J, Wu M, et al. Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study. Journal of Infection. 2022 Nov;85(5):545-56.

[37] for National Statistics (NOS) O. Coronavirus (COVID-19) Infection Survey, UK: 24 March 2023; 2023.

[38] Agency UHS. UKHSA COVID-19 data dashboard; 2026. Available from: https://ukhsa-dashboard.data.gov.uk/respiratory-viruses/covid-19.

[39] Hay JA, Minter A, Ainslie KEC, Lessler J, Yang B, Cummings DAT, et al. An open source tool to infer epidemiological and immunological dynamics from serological data: serosolver. PLOS Computational Biology. 2020 May;16(5):e1007840.

[40] Jarvis CI, Van Zandvoort K, Gimma A, Prem K, Klepac P, Rubin GJ, et al. Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. BMC Medicine. 2020 May;18(1).

[41] McGeoch LJ, Foulkes S, Whitaker H, Munro K, Khawam J, Sparkes D, et al. Effectiveness of influenza vaccination against infection in UK healthcare workers during winter 2023-24: The SIREN cohort study. Journal of Infection. 2025 Sep;91(3):106585.

[42] Wilkins D, Yuan Y, Chang Y, Aksyuk AA, Núñez BS, Wählby-Hamrén U, et al. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nature Medicine. 2023 Apr;29(5):1172-9.